Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension
Authors:
- Mustafa YildizMYMustafa Yildiz
- Serkan KahramanSKSerkan Kahraman
- Hicaz Zencirkiran AgusHAHicaz Zencirkiran Agus
- Begum UygurBUBegum Uygur
- Ali R. DemirADAli R. Demir
- Mehmet E. KalkanMKMehmet E. Kalkan
- Kadriye Memic SancarKSKadriye Memic Sancar
- Ender OnerEOEnder Oner
- İsmail GurbakIGİsmail Gurbak
- Ali K. KalkanAKAli K. Kalkan
- 10 June 2021
- journal article
- research article
- Published by Springer Nature in Herz
- Vol. 47 (2) , 158-165
Abstract
Background Pulmonary arterial hypertension (PAH) is a severe, life-threatening disorder despite the availability of specific drug therapy. A lack of endogenous prostacyclin secondary to downregulation of prostacyclin synthase in PAH may contribute to vascular pathologies. Therefore, prostacyclin and its analogs including inhaled iloprost may decrease pulmonary arterial pressure and ventricular pressure. Methods Here, we studied that acute effects of iloprost used in pulmonary vasoreactivity testing on the intracardiac conduction system in patients with PAH. A total of 35 (15 idiopathic PAH, 20 congenital heart disease) patients with PAH were included in this prospective study. Patients were divided into two groups: 22 patients with negative pulmonary vasoreactivity in group 1 and 13 with positive pulmonary vasoreactivity in group 2. Electrophysiological parameters including basic cycle length, atrium-His (AH) interval, His-ventricle (HV) interval, PR interval, QT interval, QRS duration, Wenckebach period, and sinus node recovery time (SNRT) were evaluated before and after pulmonary vasoreactivity testing in both groups. Results The AH interval (81 [74–93]; 80 [65.5–88], p = 0.019) and SNRT (907.7 ± 263.4; 854.0 ± 288.04, p = 0.027) was significantly decreased after pulmonary vasoreactivity testing. Mean right atrium pressure was found to be correlated with baseline AH (r = 0.371, p = 0.031) and SNRT (r = 0.353, p = 0.037). Conclusion Inhaled iloprost can improve cardiovascular performance in the presence of PAH, primarily through a reduction in right ventricular afterload and interventricular pressure. Decreased pressure on the interventricular septum and ventricles leads to conduction system normalization including of the AH interval and SNRT due to resolution of inflammation and edema.Keywords
This publication has 21 references indexed in Scilit:
- Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesPulmonary Circulation, 2017
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Inhaled Therapies for Pulmonary HypertensionRespiratory Care, 2015
- Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial HypertensionCirculation Research, 2014
- Atrial Electrical and Structural Remodeling Associated with Longstanding Pulmonary Hypertension and Right Ventricular Hypertrophy in HumansJournal of Cardiovascular Electrophysiology, 2012
- The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertensionTherapeutic Advances in Respiratory Disease, 2011
- Prostacyclin therapies for the treatment of pulmonary arterial hypertensionEuropean Respiratory Journal, 2008
- Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertensionAmerican Heart Journal, 2007
- Association of Nocturnal Arrhythmias with Sleep-disordered BreathingAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Aerosolised prostacyclin in adult respiratory distress syndromeThe Lancet, 1993